NCT05834855View on ClinicalTrials.gov

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating Diseases
Interventions
DRUG

Rituximab

Treatment with rituximab

Trial Locations (1)

1081 HV

RECRUITING

Amsterdam UMC, location VUmc, Amsterdam

All Listed Sponsors
collaborator

Stichting Treatmeds

UNKNOWN

lead

Amsterdam UMC, location VUmc

OTHER